Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by recurrent, paroxysmal episodes of nausea, vomiting, and abdominal discomfort in chronic cannabis users. Optimized CHS treatment data remain limited. Recent prospective evidence have demonstrated haloperidol superiority over ondansetron. Retrospective data suggest the utility of droperidol, a dopamine antagonist like haloperidol, for treating acute CHS.
Objective: To prospectively assess the utility of droperidol plus diphenhydramine to mitigate common CHS symptoms.
Methods: This was a multicenter, prospective interventional study in the emergency department (ED). Participants were administered a study regimen of droperidol and diphenhydramine to treat CHS after enrollment. The primary outcome measure was the change in VAS scores within the droperidol prospective cohort. Symptoms of nausea, vomiting, and abdominal pain were measured using a visual analogue scale (VAS) up to 120 minutes. Secondary measures assessed include repeat visits to the ED within seven days.
Results: Amongst 47 droperidol participants, VAS for nausea and vomiting declined from baseline 8.3±2.0 to 3.1±3.3 at 30 minutes post treatment (p < 0.05), and 1.4±2.4 at 120 minutes (p < 0.05). For abdominal pain, VAS mean was 7.8±2.4 at baseline declining to 3.6±2.9 at 30 minutes (p < 0.05) and 1.7±2.9 at 120 minutes (p < 0.05). Return to the ED within 7 days following droperidol was 12.9% (n=47).
Conclusion: This trial shows significant improvement in symptoms from baseline, 30 and 120 minutes post-treatment and return to the ED within a week post treatment with the study regimen.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607989 | PMC |
| http://dx.doi.org/10.2147/OAEM.S473627 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study.
Open Access Emerg Med
November 2024
Department of Emergency Medicine, Mercy Health St. Elizabeth Boardman Hospital, Boardman, OH, USA.
Background: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by recurrent, paroxysmal episodes of nausea, vomiting, and abdominal discomfort in chronic cannabis users. Optimized CHS treatment data remain limited. Recent prospective evidence have demonstrated haloperidol superiority over ondansetron.
View Article and Find Full Text PDFEffectiveness and Safety of Intravenous Medications for the Management of Acute Disturbance (Agitation and Other Escalating Behaviors): A Systematic Review of Prospective Interventional Studies.
J Acad Consult Liaison Psychiatry
June 2024
Neuropsychiatry Research and Education Group, Institute of Psychiatry, Psychology, and Neuroscience, London, United Kingdom; South London and Maudsley NHS Foundation Trust, London, United Kingdom.
Acute disturbance is a broad term referring to escalating behaviors secondary to a change in mental state, such as agitation, aggression, and violence. Available management options include de-escalation techniques and rapid tranquilization, mostly via parenteral formulations of medication. While the intramuscular route has been extensively studied in a range of clinical settings, the same cannot be said for intravenous (IV); this is despite potential benefits, including rapid absorption and complete bioavailability.
View Article and Find Full Text PDFRetrospective Review of the Efficacy of Droperidol Compared to Prochlorperazine for Headache Management in the Emergency Department.
Cureus
June 2023
Emergency Medicine, Kaiser North Valley, Roseville, USA.
Introduction Headaches are a common presentation to the emergency department, representing approximately 3% of visits. The standard treatment of headaches has consisted of either monotherapy with an antidopaminergic agent or combination therapy with an antidopaminergic agent, a non-steroidal anti-inflammatory drug (NSAID), and diphenhydramine. Although droperidol is an antidopaminergic medication, it previously was not widely used in the treatment of headaches due to safety concerns.
View Article and Find Full Text PDFParecoxib Reduced Postsurgical Pain and Facilitated Movement More Than Patient Controlled Analgesia.
Front Surg
April 2022
Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Background: Postoperative pain management is an imperative issue for patients undergoing lumbar spinal fusion surgery. Delayed pain relief is associated with poor clinical outcomes. This study compared the effects of intravenously administered patient-controlled analgesia (PCA) with intravenous parecoxib, both commonly used methods for analgesic pain control after surgery.
View Article and Find Full Text PDFRescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.
Headache
March 2012
Center for Headache and Pain, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Objective: The final section of this 3-part review analyzes published reports involving the acute treatment of migraine with opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids in the emergency department (ED), urgent care, and headache clinic settings, as well as post-discharge medications. In the Conclusion, there is a general discussion of all the therapies presented in the 3 sections.
Method: Using the terms ("migraine" AND "emergency") AND ("therapy" OR "treatment"), the author searched MEDLINE for reports from ED and urgent care settings that involved all routes of medication delivery.